OCUP רווח נקי למניה (EPS TTM) Ocuphire Pharma, Inc.

The ophthalmology sector relies on narrow niches where Ocuphire Pharma, Inc. (OCUP) minimizes risks through an alliance with a major pharmaceutical partner. Portfolio diversification with retinal drugs reduces financial vulnerability, while the success of Nyxol drops and FDA approval will serve as the primary catalysts. The trend of rolling net income per share acts as a stability detector, with the -0.55 level recording fresh values.
OCUP (Ocuphire Pharma, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For Ocuphire Pharma, Inc. (OCUP), which seeks commercial dominance of the ophthalmology market through its Ryzum and Nyxol drugs, earnings per share dynamics serve as an indicator of financial stability. The eps_ttm_co metric aggregates annual net income divided by the number of shares, excluding random fluctuations. The 12-month EPS history on GURU.Markets visualizes the business's actual ability to generate value. A stable trend confirms a margin of safety, while stagnation signals risks of missed opportunities. This analysis allows for an assessment of pipeline scaling efficiency within the context of market capitalization.